عرض بسيط للتسجيلة

المؤلفHussain, Arif
المؤلفHasan, Anwarul
المؤلفNejadi Babadaei, Mohammad Mahdi
المؤلفBloukh, Samir Haj
المؤلفChowdhury, Muhammad E.H.
المؤلفSharifi, Majid
المؤلفHaghighat, Setareh
المؤلفFalahati, Mojtaba
تاريخ الإتاحة2020-08-23T07:51:27Z
تاريخ النشر2020-10-01
اسم المنشورBiomedicine and Pharmacotherapy
المعرّفhttp://dx.doi.org/10.1016/j.biopha.2020.110559
الاقتباسprotein A. Hussain, et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomedicine & Pharmacotherapy 130 (2020) 110559
الرقم المعياري الدولي للكتاب07533322
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088960686&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/15755
الملخصThe Authors As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARS-CoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARS-CoV2 S-protein RBD. Finally, some ongoing challenges and future prospects for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV.
اللغةen
الناشرElsevier
الموضوعantibodies
Corona virus
epitope-specific vaccines (ESV)
receptor binding domain
spike protein
العنوانTargeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies
النوعArticle
رقم المجلد130


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة